Immix Biopharma Announces That All Four Relapsed/Refractory Al Amyloidosis MRDd-Negative Patients Presented At ASH 2025 Have Converted To Complete Response

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  –

–   CR rate now 95% (19 of 20 patients)   –

–    All CRs reached within 1 year of follow-up post-dosing    –

–    No relapses to-date observed for patients who have reached CR    –

–    All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month    –

–    Next NEXICART-2 Update Expected Late September, 2026    –

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.